Abstract
Following publication of the original article [1], an error was identified in Fig. 2, specifically: Fig. 2b - CL/F (mL/hr) needs to be corrected in CL/F (L/hr) Furthermore, two Supplementary Materials should also be uploaded. The added Supplementary Materials are: Additional file 7: Supplementary Materials and Methods. Additional file 8: NEO-201 protocol. This modification does not affect the integrity of the results. Clinical Pharmacokinetics of NEO-201 A. NEO-201 serum concentrations averaged for each dose level and plotted over time. B. Noncompartmental analysis of first dose of NEO-201 including the mean estimates for relevant PK parameters during dense PK sampling following the first dose given on C1D1. *Data presented as arithmetic means (%CV) due to low numbers in each group. 1 Two patients had inaccurate estimates of C1D1 clearance and volume due to an overestimation of AUCinf. 2 One patient had insufficient terminal data to accurately estimate a half-life, thus clearance and volume too. 3 Four patients had inaccurate estimates of C1D1 clearance and volume due to an overestimation of AUCinf. 4 One patient had insufficient terminal data to accurately estimate a half-life, thus clearance and volume too. 5 Two patients had inaccurate estimates of C1D1 clearance and volume due to an overestimation of AUCinf. C. Individual NEO-201 serum concentration–time profiles of 1.0 mg/kg cohort. D-E. Individual NEO-201 serum concentration–time profiles of patients in 1.5 mg/kg cohort (D) and 2.0 mg/kg cohort (E). F-G. Differences in NEO-201 distribution volume by sex (F) and body size (G).
Original language | English (US) |
---|---|
Article number | 102 |
Journal | Journal of Experimental and Clinical Cancer Research |
Volume | 42 |
Issue number | 1 |
DOIs |
|
State | Published - Dec 2023 |
Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research